Gemcitabine Combination Nano Therapies for Pancreatic Cancer

• Hoofdauteurs: Kamalika Samanta (Auteur), Saini Setua (Auteur), Sonam Kumari (Auteur), Meena Jaggi (Auteur), Murali M. Yallapu (Auteur), Subhash C. Chauhan (Auteur)
• Formaat: Boek
• Gepubliceerd in: MDPI AG, 2019-11-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreat...